Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Arenobufagin derivative ZM-226 has antitumor activity with low cardiotoxicity

March 30, 2021

Mission Therapeutics discovers USP30 inhibitors

March 30, 2021

New platinum IV complexes synthesized at VUAB Pharma

March 30, 2021

Inflazome divulges new NLRP3 inflammasome inhibitors

March 30, 2021

Enrollment starts in phase II study of teverelix trifluoroacetate in prostate cancer

March 30, 2021

Wigen Biomedicine Technology discovers Wee1hu inhibitors

March 29, 2021

New ATX inhibitors identified by Humanwell Healthcare, collaborators

March 29, 2021

Shanghai Institute of Materia Medica identifies new AXL and/or MET inhibitors

March 29, 2021

Jiangsu Chia Tai Tianqing Pharmaceutical Group and collaborators describe GTPase KRAS inhibitors

March 29, 2021

HMPL-306 enters international phase I studies in solid tumors and hematological malignancies

March 29, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...